Navigation Links
Launching a global alliance for pharmacogenomics
Date:4/14/2008

Leaders at the National Institutes of Health and the Center for Genomic Medicine in Japan have signed a letter of intent creating a Global Alliance for Pharmacogenomics. The effort aims to identify genetic factors that contribute to individual responses to medicines, including rare and dangerous side effects. The results of such work will eventually help doctors optimize the safety and effectiveness of drugs for each patient.

U.S. scientists joining the alliance are members of the NIH Pharmacogenetics Research Network, a consortium of research groups that study how genetic factors influence the way drugs work in and are handled by the body.

Japanese scientists in the alliance represent the newly created Center for Genomic Medicine, a component of the RIKEN Yokohama Institute that conducts high-throughput analyses of human genes involved in diseases and drug responses.

Signers of the agreement include the directors of three of the National Institutes of Health: Jeremy M. Berg, Ph.D., director of the National Institute of General Medical Sciences; Elizabeth G. Nabel, M.D., director of the National Heart, Lung, and Blood Institute; and John E. Niederhuber, M.D., director of the National Cancer Institute.

"By bringing together our resources, we will advance the understanding of how changes in DNA affect our responses to medicines. Thus we can begin to realize the promise of personalized medicine," said Yusuke Nakamura, M.D., Ph.D., director of the Center for Genomic Medicine at RIKEN.

We expect this international agreement to speed scientific discovery and the translation of results into improved treatments for cancer, heart disease and other serious conditions, said NIH Director Elias A. Zerhouni, M.D. Ultimately, physicians worldwide will be able to tailor the treatment of each patient--one of the great frontiers of health care today.

Initial projects will focus on:

  • Understanding genetic factors that influence the effectiveness of breast cancer treatments (aromatase inhibitors)

  • Determining the optimal length of treatment for two drugs used to treat early stage breast cancer (cyclophosphamide and either doxorubicin or paclitaxel)

  • Discovering new genetic factors linked to serious side effects from certain pancreatic cancer drugs (gemcitabine and bevacizumab)

  • Exploring how genes contribute to drug-induced long QT syndrome, an irregular heart rhythm that can cause sudden cardiac arrest

  • Working with the International Warfarin Consortium to tailor initial doses of the anti-clotting drug warfarin based on the genetic profiles of patients

A steering committee will manage the alliance and will meet twice a year to discuss progress, future directions, intellectual property issues, the approval of additional members and communication with the public. Alliance members will share their data and their research results with the scientific community.

The letter of intent is available at http://www.nigms.nih.gov/Initiatives/PGRN/GAP/. This site also includes acknowledgements of the research centers that provided DNA samples essential to perform the work.


'/>"/>

Contact: Alisa Machalek
alisa.machalek@nih.gov
301-496-7301
NIH/National Institute of General Medical Sciences
Source:Eurekalert

Related biology news :

1. Regional nuclear conflict would create near-global ozone hole, says CU-Boulder study
2. At ACS national meeting, global initiative set to tackle water issues
3. Harmful algae taking advantage of global warming
4. Despite awareness of global warming Americans concerned more about local environment
5. Black carbon pollution emerges as major player in global warming
6. Speaker, judges set for Global Venture Challenge
7. Pew Institute teams with Chantecaille Cosmetics to protect global marine life
8. Smithsonian announces Global Forest Carbon Research Initiative
9. Will global warming increase plant frost damage?
10. Destruction of Sumatra forests driving global climate change and species extinction
11. U-M researchers release most detailed global study of genetic variation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... announced today that on December 13, 2016, it received ... Nasdaq Stock Market LLC which acknowledged that, as of ... common stock had been at $1.00 or greater for ... with Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the ... market is expected to grow from USD 4.03 billion ... a CAGR of 29.3% between 2016 and 2022. The ... demand for smart devices, government initiatives, and increasing penetration ... is expected to grow at a high rate during ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition ... Service, Application Area, End User, And Region - Global Forecast to 2021", published ... in 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:1/13/2017)... ... January 13, 2017 , ... FireflySci, in ... its customers three new solutions for measurements where traditional cuvette applications are not ... customer has an oddly-shaped sample that would not fit into a typical cuvette ...
(Date:1/12/2017)... ... January 12, 2017 , ... After her brain cancer ... gave her only a few months to live. Now a paper publishing January ... Rosendahl’s disease and increased both the quantity and quality of her life: Adding ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... enhanced the platform to accommodate increasingly complex and sophisticated deployments, resulting in ... more. In addition to these improvements, the latest release brings enhanced data ...
(Date:1/11/2017)... YORK , Jan. 11, 2017  Brian Mehling, ... and founder of Blue Horizon International (BHI), will be ... Davos from January 17-20, 2017. ... global conference. The theme of this year,s ... the program,s 400 sessions will address strategies for fostering ...
Breaking Biology Technology: